Comparing the current results to its competitors, Orthopediatrics reported Revenue increase in the 1 quarter 2026 by 11.73 % year on year. The sales growth was above Orthopediatrics's competitors' average revenue growth of 7.31 %, achieved in the same quarter.
Orthopediatrics Corp, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 18.43 %
Orthopediatrics's Comment on Competition and Industry Peers
The company is a diversified orthopedic firm specializing exclusively in the pediatric market, focusing on pediatric orthopedic surgery and bracing. It supports pediatric orthopedic surgical societies through donations and conducts training workshops. Its product portfolio includes 87 surgical and bracing systems. The company collaborates with surgeons and operates a scalable business model, targeting high-volume children's hospitals that perform most pediatric procedures. It works with ISO 13485 certified suppliers to ensure quality and cost control. Competitors identified in filings include IMS Health, Inc.
Company's competitiveness improved within Overall company, with revenue growth of 11.73 % and its market share increased to approx. 0.26 %. << More on KIDS Market Share.
*Market share is calculated based on total revenue.
November 13, 2025
Marching Forward in Pediatric Orthopedics: OrthoPediatrics Unveils New Bracing Solutions Amidst Financial Recovery In the heart of Warsaw, Indiana, OrthoPediatrics Corp. continues to carve a niche in pediatric orthopedics with an unwavering commitment to innovation and progress. On November 13, 2025, the company proudly announced the expansion of its Specialty Bracing portfolio, unveiling two cutting-edge products: the PediHip Rigid Brace and the PediHip Modular Abduction Systems. These additions bring the OrthoPediatrics Specialty Bracing (OPSB) division to a robust lineup of 31 systems each designed with the unique and evolving needs of pediatric care in mind.The launch of these pioneering bracing systems ...
October 28, 2025
OrthoPediatrics Corp. Achieves FDA Approval for New Pediatric Orthopedic System Amidst Market Challenges Warsaw, Ind., Oct. 28, 2025 OrthoPediatrics Corp. (Nasdaq: KIDS), a leader in pediatric orthopedic medical devices, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its 3P Pediatric Plating Platform Small-Mini System. This system is the second in a series of innovative products within the 3P family designed to advance pediatric bone health. With this new FDA approval, the company continues to bolster its position as a pioneering force in the specialized area of pediatric orthopedics, marking its sixth FDA endorsement in 2025 alone.The introduction of the Small-Mi...
November 26, 2024
OrthoPediatrics Corp. Braces for Growth with DF2 Innovations In the niche yet steadily expanding market of pediatric orthopedics, OrthoPediatrics Corp. has unveiled significant enhancements to its DF2 Brace a cornerstone product of their Specialty Bracing business. This development underscores the company’s commitment to its mission: advancing pediatric orthopedic care through specialized solutions.Based in Warsaw, Indiana, OrthoPediatrics stands distinct in its singular focus on children s orthopedics. The latest updates to the DF2 Brace include expanded indications for use, enhanced sizing options, and entry into additional international markets. These modifications not only broaden the potential patient...
September 12, 2024
In a strategic move poised to reshape the landscape of pediatric orthopedic care, OrthoPediatrics Corp. has officially announced the launch of its Enabling Technologies Division. The initiative aims to develop cutting-edge solutions that enhance surgical efficiencies and improve patient outcomes in children with musculoskeletal conditions. Founded with a mission to address the unique orthopedic needs of children, OrthoPediatrics has long been a leader in pediatric-specific surgical products. The establishment of the Enabling Technologies Division signals the company s commitment to innovation in medical technology and reflects its dedication to delivering specialized care tailored to younger patients. Innova...
May 15, 2024
OrthoPediatrics Corp., a renowned orthopedic company, has reaffirmed its commitment to the orthopedic community by reinforcing its long-term sponsorship as an Emerald Sponsor at the 2024 EPOSNA Annual Meeting. This continued partnership serves as a testament to OrthoPediatrics Corp. s dedication to advancing pediatric orthopedic care and supporting professional development within the industry.I. Background:The EPOSNA Annual Meeting is an esteemed gathering of professionals and experts in the field of pediatric orthopedics. It serves as a platform for exchanging knowledge, presenting the latest advancements in pediatric orthopedics, and fostering collaborations. OrthoPediatrics Corp., a market leader speciali...
May 2, 2024
The cutting-edge eLLi surgical device, which has been crafted to address severe pathology associated with EOS, signals a notable shift in technology used to extend growing rods in pediatric patients. Faced with a condition that can potentially be life-threatening due to the likelihood of thoracic insufficiency, these patients require effective and safe methods of orthopedic assistance.The eLLi Surgical device stands out due to its non-invasive approach. The goal of the eLLi system is to deliver an advanced and reliable system of extending growing rods with increased force, superior distraction precision, and enhanced mechanical reliability that are unmatched by current technologies. Importantly, this would a...
Apyx Medical Corporation follows a business model that centers around the development, manufacturing, and marketing of medical devices used in the field of aesthetics and surgical markets. The company focuses on creating innovative products that improve patient outcomes and enhance the effectiveness of surgical procedures. Apyx Medical Corporation sells its devices primarily through a direct sales force in the United States, while utilizing a combination of direct sales representatives and distributors in international markets.
Procept Biorobotics Corporation follows a business model focused on developing medical robotics solutions for urology procedures. Their flagship product, the AquaBeam System, utilizes waterjet technology to perform minimally invasive surgeries for patients with benign prostatic hyperplasia. The company aims to improve patient outcomes and reduce healthcare costs by providing an innovative and efficient alternative to traditional surgical methods.
Nuwellis Inc.'s business model revolves around developing and commercializing innovative therapeutic solutions, predominantly focusing on fluid management to improve outcomes for patients with critical illnesses. They aim to provide advanced medical devices and solutions to healthcare professionals, addressing the pressing need for better fluid management in critical care settings.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Medinotec Inc is a medical technology company that operates on a business model focused on developing and providing innovative healthcare solutions, such as medical devices and software, to improve patient care and outcomes. Their products and services cater to healthcare professionals and institutions, offering advanced technology solutions in the medical field.
Sources:
Orthopediatrics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Orthopediatrics Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
